TO CONSULTING AGREEMENT. This Amendment No. 5 to Consulting Agreement (“Amendment No. 4”) is made as of February 1, 2021, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being Oxx Xxxxxxx Xxxxxx, Building 1400 West, Suite 14303, Cambridge, MA 02139 (“Company”) and Dxxxxxxx Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being 90 Xxxxxx Xxxx, Xxxxxxxxxxxx, XX 00000 (“Dxxxxxxx”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Dxxxxxxx and the Company dated as of March 13, 2013 (“Agreement”).
TO CONSULTING AGREEMENT. This Amendment No. 1 (“Amendment”), dated as of November 4, 2002 and effective as of January 1, 2002 (the “Effective Date”) is entered into by and between Schrödinger, Inc. (“Schrödinger” or “Company”), a Delaware corporation with an address at 000 Xxxx 00xx Xxxxxx, 00xx Xxxxx, Xxx Xxxx, XX 00000, and Xxxxxxx X. Xxxxxxxx (“Consultant”), an individual with an address at [**].
TO CONSULTING AGREEMENT. Dear Rxxxxxx: This is in reference to the Consulting Agreement between VL42, d/b/a Omega Therapeutics, Inc., and Rxxxxxx X. Xxxxx, Ph.D. dated November 7, 2016 (the “Agreement”). All capitalized terms used in this letter and not otherwise defined in this letter shall have the same meaning as in the Agreement.
TO CONSULTING AGREEMENT. For X. Xxxxx Xxxx (Anticipated as of February 28, 2019) Grant Name Xxxxx Xxxxx Granted Vested Unvested Exercisable Exercised / Released Outstanding Restricted Shares Scheduled to Vest on 04/01/2019 02/26/2016 RS CIC- D&D $0.00 46,200 42,350 3,850 0 42,350 3,850 3,850 03/02/2017 RS CIC- D&D $0.00 36,135 21,077 15,058 0 21,077 15,058 3,011 03/02/2018 RS CIC D&D $0.00 22,585 5,646 16,939 0 5,646 16,939 1,882 03/02/2018 RS (Market Based) CIC-D&D $0.00 45,172 5,646 39,526 0 5,646 39,526 2,823 Total 150,092 74,719 75,373 0 74,719 75,373 11,566
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is made as of April 30, 2014 (“Effective Date”), by and between Dxxxxxxx Advisors, LLC (“Consultant”), a corporation located at 90 Xxxxxx Xxxx, Xxxxxxxxxxxx, XX 00000 and Vedantra Pharmaceuticals, Inc., a Delaware corporation (“Company”), located at One Kxxxxxx Square, Building 1000 Xxxx, Xxxxx 00000, Xxxxxxxxx, XX 00000. Capitalized terms use but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Dxxxxxxx Advisors, LLC and the Company dated as of March 13, 2014 (“Agreement”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is entered into by and between AlloVir, Inc. (formerly ViraCyte, Inc.), a Delaware corporation (the “Company”), and Xxx Xxxx (“Consultant”), effective generally as of January 1, 2020 (the “Effective Date”).
TO CONSULTING AGREEMENT. THIS AMENDMENT No. 1 TO CONSULTING AGREEMENT (“Amendment No. 1”) is effective as of March 3, 2023 (hereinafter “Effective Date”) by and between BridgeBio Pharma, Inc. (hereinafter “Company”), a Delaware corporation with offices at 000 Xxxxxxx Xxxxxx, Xxxx Xxxx, Xxxxxxxxxx 00000, and Xxxxx XxXxxxxxx (hereinafter “Consultant”), located at [***] (each herein referred to as a “Party” and collectively as “Parties”).
TO CONSULTING AGREEMENT. THIS ADDENDUM NO. 1 TO AGREEMENT, dated as of July 8, 2020, is entered into by GNC Holdings, Inc. (“Merchant”) and a joint venture comprised of Tiger Capital Group, LLC (“Tiger”) and Great American Group, LLC (“GA”) (Tiger together with GA, “Consultant”).
TO CONSULTING AGREEMENT. Amendment No. 1 dated December 3, 1999 to the Consulting Agreement (the "Consulting Agreement") dated as of the 1st day of November, 1999 by Urban Cool Network, Inc. (the "Company") and RMH Consulting Corp. (the "Consultant").
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (as defined below) (the “Amendment”) is entered into on December ___, 2007 by and among NovaRay, Inc., a Delaware corporation (the “Company”) and Fountainhead Capital Partners Limited (“Consultant”) (each a “Party” and collectively referred to hereafter as the “Parties”).
